{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:23:24Z","timestamp":1790256204984,"version":"4.1.0"},"publisher-location":"Chichester, UK","reference-count":65,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd005166.pub2","type":"reference-entry","created":{"date-parts":[[2007,1,25]],"date-time":"2007-01-25T13:35:23Z","timestamp":1169732123000},"source":"Crossref","is-referenced-by-count":39,"title":["Drugs improving insulin resistance for non-alcoholic fatty liver disease and\/or non-alcoholic steatohepatitis"],"prefix":"10.1002","author":[{"given":"Francesco","family":"Angelico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Burattin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Alessandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Del Ben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Lirussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,1,24]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD005166.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1572-0241.2005.41583.x","article-title":"A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease","volume":"100","author":"Bugianesi","year":"2005","journal-title":"Americal Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD005166.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1542-3565(04)00457-4","article-title":"A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis","volume":"2","author":"Sanyal","year":"2004","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD005166.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2036.2004.01888.x","article-title":"Metformin in the treatment of patients with non-alcoholic steatohepatitis","volume":"19","author":"Uygun","year":"2004","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"9","key":"10.1002\/14651858.CD005166.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1111\/j.1572-0241.2001.04129.x","article-title":"Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study","volume":"96","author":"Abdelmalek","year":"2001","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD005166.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1572-0241.2001.03553.x","article-title":"A pilot study of thiazolidinedione, troglitazone in nonalcoholic steatohepatitis","volume":"96","author":"Caldwell","year":"2001","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD005166.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"Fronzo","year":"2005","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD005166.pub2-BIB7|cit7","first-page":"12","article-title":"Assessment of insulin resistance and effect of metformin in nonalcoholic steatohepatitis - a preliminary report","volume":"23","author":"Duseja","year":"2004","journal-title":"Indian Journal of Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD005166.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1023\/B:DDAS.0000004523.51779.7c","article-title":"Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with type 2 diabetes and psoriasis","volume":"48","author":"Itoh","year":"2003","journal-title":"Digestive Diseases and Sciences"},{"issue":"4","key":"10.1002\/14651858.CD005166.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1053\/meta.2001.21691","article-title":"Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy. A randomized controlled trial","volume":"50","author":"Katoh","year":"2001","journal-title":"Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD005166.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2337\/diacare.25.5.815","article-title":"Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction","volume":"25","author":"Lebovitz","year":"2002","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD005166.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.20092","article-title":"Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial","volume":"39","author":"Lindor","year":"2004","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD005166.pub2-BIB12|cit12","first-page":"222","article-title":"Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent","volume":"15","author":"Lirussi","year":"2002","journal-title":"Diabetes, Nutrition Metabolism"},{"issue":"6","key":"10.1002\/14651858.CD005166.pub2-BIB13|cit13","first-page":"406","article-title":"Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary\/pharmacological treatment. A pilot study","volume":"36","author":"Magalotti","year":"2004","journal-title":"Digestive and Liver Disease"},{"issue":"9285","key":"10.1002\/14651858.CD005166.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(01)06042-1","article-title":"Metformin in non-alcoholic steatohepatitis","volume":"358","author":"Marchesini","year":"2001","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD005166.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1111\/j.1572-0241.2001.03809.x","article-title":"Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus","volume":"96","author":"Menon","year":"2001","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD005166.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2036.2004.02025.x","article-title":"Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial","volume":"20","author":"Nair","year":"2004","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD005166.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1053\/jhep.2003.50420","article-title":"Improved nonalcoholic steatohepatitis after 48 weeks of treatment with PPAR-gamma ligand rosiglitazone","volume":"38","author":"Neuschwander-Tetri","year":"2003","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD005166.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0168-8278(03)00027-8","article-title":"Interim results of a study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis","volume":"38","author":"Neuschwander-Tetri","year":"2003","journal-title":"Journal of Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD005166.pub2-BIB19|cit19","first-page":"873","article-title":"A case of obese type 2 diabetes mellitus associated with nonalcoholic steatohepatitis (NASH) treated with a combined therapy of glimepiride and insulin","volume":"46","author":"Nohara","year":"2003","journal-title":"Journal of the Japan Diabetes Society"},{"issue":"7","key":"10.1002\/14651858.CD005166.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s002280050514","article-title":"Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency","volume":"54","author":"Ott","year":"1998","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD005166.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.20012","article-title":"A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis","volume":"39","author":"Promrat","year":"2004","journal-title":"Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD005166.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/j.1365-2036.2005.02420.x","article-title":"A phase 2 clinical trial of metformin as a treatment for non-diabetic paedriatic non-alcoholic steatohepatitis","volume":"21","author":"Schwimmer","year":"2005","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD005166.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1053\/S1542-3565(03)00198-8","article-title":"Effect of piglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity","volume":"1","author":"Shadid","year":"2003","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD005166.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.2337\/diacare.26.11.3148","article-title":"Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity","volume":"26","author":"Shadid","year":"2003","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1002\/14651858.CD005166.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2337\/diacare.20.6.925","article-title":"Contraindications to metformin therapy in patients with NIDDM","volume":"20","author":"Sulkin","year":"1997","journal-title":"Diabetes Care"},{"issue":"9303","key":"10.1002\/14651858.CD005166.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(02)07566-9","article-title":"Metformin in non-alcoholic steatohepatitis","volume":"359","author":"Urso","year":"2002","journal-title":"Lancet"},{"issue":"35","key":"10.1002\/14651858.CD005166.pub2-BIB27|cit27","first-page":"26","article-title":"Metformin therapy for fatty liver","volume":"145","author":"Gensthaler","year":"2000","journal-title":"Pharmazeutische Zeitung"},{"issue":"2","key":"10.1002\/14651858.CD005166.pub2-BIB28|cit28","first-page":"94","article-title":"Treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"21","author":"Leiss","year":"2003","journal-title":"Verdauungskrankheiten"},{"issue":"5","key":"10.1002\/14651858.CD005166.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1440-1746.2003.02958.x","article-title":"Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases","volume":"18","author":"Angelico","year":"2003","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD005166.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1210\/jc.2004-1024","article-title":"Insulin resistance, the metabolic syndrome and nonalcoholic fatty liver disease","volume":"90","author":"Angelico","year":"2005","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD005166.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"16","author":"Angulo","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD005166.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1053\/bega.2002.0327","article-title":"Treatment of non-alcoholic steatohepatitis","volume":"16","author":"Angulo","year":"2002","journal-title":"Best Practice & Research Clinical Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD005166.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/0016-5085(94)90235-6","article-title":"Non-alcoholic steatohepatitis: an expanded clinical entity","volume":"107","author":"Bacon","year":"1994","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD005166.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/hep.510230513","article-title":"Prediction of risk of liver disease by alcohol intake, sex and age: a prospective population study","volume":"23","author":"Becker","year":"1996","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD005166.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/archsurg.133.1.84","article-title":"Unsuspected cirrhosis discovered during elective obesity operations","volume":"133","author":"Brolin","year":"1998","journal-title":"Archives of Surgery"},{"issue":"9","key":"10.1002\/14651858.CD005166.pub2-BIB36|cit36","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","author":"Brunt","year":"1999","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD005166.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/gast.2002.34168","article-title":"Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma","volume":"123","author":"Bugianesi","year":"2002","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD005166.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/hep.510290347","article-title":"Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease","volume":"29","author":"Calwell","year":"1999","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD005166.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2001-12927","article-title":"Etiopathogenesis of non-alcoholic steatohepatitis","volume":"21","author":"Chitturi","year":"2001","journal-title":"Seminars in Liver Disease"},{"issue":"2","key":"10.1002\/14651858.CD005166.pub2-BIB40|cit40","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1053\/jhep.2002.30692","article-title":"NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome","volume":"35","author":"Chitturi","year":"2002","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD005166.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \"hits\"?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD005166.pub2-BIB42|cit42","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/sim.4780060325","article-title":"Methods for combining randomized clinical trials: strengths and limitations","volume":"6","author":"DeMets","year":"1987","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD005166.pub2-BIB43|cit43","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"6","key":"10.1002\/14651858.CD005166.pub2-BIB44|cit44","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/hep.20251","article-title":"Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss","volume":"39","author":"Dixon","year":"2004","journal-title":"Hepatology"},{"issue":"7109","key":"10.1002\/14651858.CD005166.pub2-BIB45|cit45","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"3","key":"10.1002\/14651858.CD005166.pub2-BIB46|cit46","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1046\/j.1440-1746.2003.02989.x","article-title":"Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?","volume":"18","author":"Farrell","year":"2003","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD005166.pub2-BIB47|cit47","first-page":"322","article-title":"Alcoholic hepatitis: no glucocorticosteroids?","volume-title":"Steatohepatitis (NASH and ASH), Falk Symposium 121","author":"Gluud","year":"2001"},{"key":"10.1002\/14651858.CD005166.pub2-BIB48|cit48","unstructured":"Gluud C Als-Nielsen B D'Amico G Fingerhut A Gluud LL Khan S Hepato-Biliary Group About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2006, Issue 3. Art. No.: LIVER"},{"key":"10.1002\/14651858.CD005166.pub2-BIB49|cit49","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006] The Cochrane Library, Issue 4, 2006 Chichester, UK John Wiley & sons, Ltd"},{"issue":"11","key":"10.1002\/14651858.CD005166.pub2-BIB50|cit50","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD005166.pub2-BIB51|cit51","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hep.1840010511","article-title":"Formulation and application of a numerical score system for assessing histological activity in asymptomatic chronic active hepatitis","volume":"1","author":"Knodell","year":"1981","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD005166.pub2-BIB52|cit52","doi-asserted-by":"crossref","first-page":"549-58, viii-ix","DOI":"10.1016\/j.cld.2004.04.010","article-title":"Nonalcoholic fatty liver disease in the pediatric population","volume":"8","author":"Lavine","year":"2004","journal-title":"Clinics in Liver Disease"},{"issue":"5","key":"10.1002\/14651858.CD005166.pub2-BIB53|cit53","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0002-9343(99)00271-5","article-title":"Association of nonalcoholic fatty liver disease with insulin resistance","volume":"107","author":"Marchesini","year":"1999","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD005166.pub2-BIB54|cit54","first-page":"1844","article-title":"Nonalcoholic fatty liver disease: a feature of the metabolic syndrome","volume":"8","author":"Marchesini","year":"50","journal-title":"Diabetes"},{"issue":"3","key":"10.1002\/14651858.CD005166.pub2-BIB55|cit55","first-page":"255","article-title":"Update on nonalcoholic fatty liver disease","volume":"34","author":"McCullough","year":"2002","journal-title":"Journal of Clinical Investigation"},{"issue":"9128","key":"10.1002\/14651858.CD005166.pub2-BIB56|cit56","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD005166.pub2-BIB57|cit57","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1053\/jhep.2003.50193","article-title":"Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference","volume":"37","author":"Neuschwander-Tetri","year":"2003","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005166.pub2-BIB58|cit58","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1053\/jhep.2000.17894","article-title":"Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study","volume":"32","author":"Poonawala","year":"2000","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD005166.pub2-BIB59|cit59","unstructured":"Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2003"},{"issue":"4","key":"10.1002\/14651858.CD005166.pub2-BIB60|cit60","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"Royle","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"5","key":"10.1002\/14651858.CD005166.pub2-BIB61|cit61","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1053\/gast.2001.23256","article-title":"Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities","volume":"120","author":"Sanyal","year":"2001","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD005166.pub2-BIB62|cit62","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD005166.pub2-BIB63|cit63","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejim.2003.12.008","article-title":"Non-alcoholic steatohepatitis: review of a growing medical problem","volume":"15","author":"Sligte","year":"2004","journal-title":"European Journal of Internal Medicine"},{"key":"10.1002\/14651858.CD005166.pub2-BIB64|cit64","doi-asserted-by":"crossref","unstructured":"Wang RT Koretz RL Yee HF Weight reduction for non-alcoholic fatty liver (Protocol) The Cochrane Database of Systematic Reviews 2002, Issue 1. Art. No.: CD003619. DOI: 10.1002\/14651858.CD003619","DOI":"10.1002\/14651858.CD003619"},{"issue":"4","key":"10.1002\/14651858.CD005166.pub2-BIB65|cit65","first-page":"450","article-title":"Nonalcoholic fatty liver disease: an agenda for clinical research","volume":"34","author":"Younossi","year":"2002","journal-title":"Hepatology"}],"updated-by":[{"DOI":"10.1002\/14651858.cd005166.pub3","type":"withdrawal","label":"Withdrawal","source":"publisher","updated":{"date-parts":[[2013,4,30]],"date-time":"2013-04-30T00:00:00Z","timestamp":1367280000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD005166.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:45:46Z","timestamp":1628545546000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD005166.pub2"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Angelico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2007,1,24]]},"references-count":65,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005166.pub2","relation":{"withdrawal":[{"id-type":"doi","id":"10.1002\/14651858.CD005166.pub3","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2007,1,24]]}}}